Local airways immune modifications induced by oral bacterial extracts in chronic bronchitis

M. Lusuardi, A. Capelli, S. Carli, E. L. Spada, A. Spinazzi, C. F. Donner

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Bacterial extracts can act as immune stimulants and in some instances have been used, rather empirically, to prevent recurrent infections in the nonimmunocompromised host. Some agents are administered via oral route with the goal to increase airways immune defenses. In animal models and in normal humans, gut-associated lymphoid tissue (GALT) stimulation is able to induce a generalized response by the whole mucosal-associated lymphoid tissue (MALT). The aim of this placebo-controlled, double-blind, parallel-group study was to evaluate whether the stimulation of the GALT through oral administration of a polyvalent bacterial extract (BE) could lead to significant immune modifications either systemically or locally in the respiratory tract in patients suffering from chronic bronchitis. We selected 20 subjects (5 nonsmokers, 6 smokers, and 9 ex-smokers) for at least 3 years. According to a balanced-block randomization method, ten patients received active treatment and ten received placebo. Either drug or placebo was to be taken as one capsule daily the first 10 days of 3 consecutive months. Each capsule of the active product contained 7 mg of a BE obtained from eight different bacterial strains. On entry (T0) and 90 days after beginning of treatment (T90), all patients underwent bronchoalveolar lavage (BAL) and peripheral blood withdrawal to assay BAL fluids and serum samples for immune parameters. The BAL recoveries, cellularity, cell differentials, and lymphocyte subsets (CD19, CD3, CD4, CD8) did not show significant differences. IgG/albumin and IgA/albumin values were not significantly different, but IgA/albumin was significantly increased in the treatment (T0=0.14, 0.01 to 0.27, median and range, T90=0.15, 0.08 to 0.45, p=0.028) vs the placebo group when data from current smokers were excluded. Functional tests on alveolar macrophages (AM) (leading front stimulated motility and superoxide anion-O2/--release) showed a significant increase of random migration (T0=10.6, 7.0 to 23.6, T90=13.4, 8.1 to 28.8 μm, p=0.02) and of stimulated motility after FMLP 10- 7 M (T0=13.2, 8.3 to 46.4, T90=18.3, 8.4 to 49.6 μm, p=0.04), a significant increase of O2 - release in basal conditions (T0=6.0, 1.7 to 30.5 nM/106 AM/10', T90=11.1, 5.5 to 24.5, p=0.05) and after stimulation with opsonized zymosan (T0=17.7, 4.7 to 35.2, T90=22.1, 13.8 to 53.3, p=0.009) in the treatment group only. Data were not significantly different in the placebo group between T0 and T90. No modifications in systemic immunity were ever observed. Our data demonstrate that oral administration of a BE can increase immune defenses in the respiratory tract of patients with chronic bronchitis, without apparently altering systemic immunity. This confirms the possibility of a preferential traffic of immune information across the MALT and supports a rationale for experimental trials with oral treatments using BEs in the prevention of chronic bronchitis exacerbations.

Original languageEnglish
Pages (from-to)1783-1791
Number of pages9
JournalChest
Volume103
Issue number6
Publication statusPublished - 1993

Fingerprint

Chronic Bronchitis
Lymphoid Tissue
Placebos
Albumins
Alveolar Macrophages
Bronchoalveolar Lavage
Respiratory System
Immunoglobulin A
Capsules
Oral Administration
Immunity
Therapeutics
Zymosan
Lymphocyte Subsets
Bronchoalveolar Lavage Fluid
Random Allocation
Superoxides
Immune Sera
Animal Models
Immunoglobulin G

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Lusuardi, M., Capelli, A., Carli, S., Spada, E. L., Spinazzi, A., & Donner, C. F. (1993). Local airways immune modifications induced by oral bacterial extracts in chronic bronchitis. Chest, 103(6), 1783-1791.

Local airways immune modifications induced by oral bacterial extracts in chronic bronchitis. / Lusuardi, M.; Capelli, A.; Carli, S.; Spada, E. L.; Spinazzi, A.; Donner, C. F.

In: Chest, Vol. 103, No. 6, 1993, p. 1783-1791.

Research output: Contribution to journalArticle

Lusuardi, M, Capelli, A, Carli, S, Spada, EL, Spinazzi, A & Donner, CF 1993, 'Local airways immune modifications induced by oral bacterial extracts in chronic bronchitis', Chest, vol. 103, no. 6, pp. 1783-1791.
Lusuardi, M. ; Capelli, A. ; Carli, S. ; Spada, E. L. ; Spinazzi, A. ; Donner, C. F. / Local airways immune modifications induced by oral bacterial extracts in chronic bronchitis. In: Chest. 1993 ; Vol. 103, No. 6. pp. 1783-1791.
@article{cf6b377f91b446dcb62545a9088ea07e,
title = "Local airways immune modifications induced by oral bacterial extracts in chronic bronchitis",
abstract = "Bacterial extracts can act as immune stimulants and in some instances have been used, rather empirically, to prevent recurrent infections in the nonimmunocompromised host. Some agents are administered via oral route with the goal to increase airways immune defenses. In animal models and in normal humans, gut-associated lymphoid tissue (GALT) stimulation is able to induce a generalized response by the whole mucosal-associated lymphoid tissue (MALT). The aim of this placebo-controlled, double-blind, parallel-group study was to evaluate whether the stimulation of the GALT through oral administration of a polyvalent bacterial extract (BE) could lead to significant immune modifications either systemically or locally in the respiratory tract in patients suffering from chronic bronchitis. We selected 20 subjects (5 nonsmokers, 6 smokers, and 9 ex-smokers) for at least 3 years. According to a balanced-block randomization method, ten patients received active treatment and ten received placebo. Either drug or placebo was to be taken as one capsule daily the first 10 days of 3 consecutive months. Each capsule of the active product contained 7 mg of a BE obtained from eight different bacterial strains. On entry (T0) and 90 days after beginning of treatment (T90), all patients underwent bronchoalveolar lavage (BAL) and peripheral blood withdrawal to assay BAL fluids and serum samples for immune parameters. The BAL recoveries, cellularity, cell differentials, and lymphocyte subsets (CD19, CD3, CD4, CD8) did not show significant differences. IgG/albumin and IgA/albumin values were not significantly different, but IgA/albumin was significantly increased in the treatment (T0=0.14, 0.01 to 0.27, median and range, T90=0.15, 0.08 to 0.45, p=0.028) vs the placebo group when data from current smokers were excluded. Functional tests on alveolar macrophages (AM) (leading front stimulated motility and superoxide anion-O2/--release) showed a significant increase of random migration (T0=10.6, 7.0 to 23.6, T90=13.4, 8.1 to 28.8 μm, p=0.02) and of stimulated motility after FMLP 10- 7 M (T0=13.2, 8.3 to 46.4, T90=18.3, 8.4 to 49.6 μm, p=0.04), a significant increase of O2 - release in basal conditions (T0=6.0, 1.7 to 30.5 nM/106 AM/10', T90=11.1, 5.5 to 24.5, p=0.05) and after stimulation with opsonized zymosan (T0=17.7, 4.7 to 35.2, T90=22.1, 13.8 to 53.3, p=0.009) in the treatment group only. Data were not significantly different in the placebo group between T0 and T90. No modifications in systemic immunity were ever observed. Our data demonstrate that oral administration of a BE can increase immune defenses in the respiratory tract of patients with chronic bronchitis, without apparently altering systemic immunity. This confirms the possibility of a preferential traffic of immune information across the MALT and supports a rationale for experimental trials with oral treatments using BEs in the prevention of chronic bronchitis exacerbations.",
author = "M. Lusuardi and A. Capelli and S. Carli and Spada, {E. L.} and A. Spinazzi and Donner, {C. F.}",
year = "1993",
language = "English",
volume = "103",
pages = "1783--1791",
journal = "Chest",
issn = "0012-3692",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Local airways immune modifications induced by oral bacterial extracts in chronic bronchitis

AU - Lusuardi, M.

AU - Capelli, A.

AU - Carli, S.

AU - Spada, E. L.

AU - Spinazzi, A.

AU - Donner, C. F.

PY - 1993

Y1 - 1993

N2 - Bacterial extracts can act as immune stimulants and in some instances have been used, rather empirically, to prevent recurrent infections in the nonimmunocompromised host. Some agents are administered via oral route with the goal to increase airways immune defenses. In animal models and in normal humans, gut-associated lymphoid tissue (GALT) stimulation is able to induce a generalized response by the whole mucosal-associated lymphoid tissue (MALT). The aim of this placebo-controlled, double-blind, parallel-group study was to evaluate whether the stimulation of the GALT through oral administration of a polyvalent bacterial extract (BE) could lead to significant immune modifications either systemically or locally in the respiratory tract in patients suffering from chronic bronchitis. We selected 20 subjects (5 nonsmokers, 6 smokers, and 9 ex-smokers) for at least 3 years. According to a balanced-block randomization method, ten patients received active treatment and ten received placebo. Either drug or placebo was to be taken as one capsule daily the first 10 days of 3 consecutive months. Each capsule of the active product contained 7 mg of a BE obtained from eight different bacterial strains. On entry (T0) and 90 days after beginning of treatment (T90), all patients underwent bronchoalveolar lavage (BAL) and peripheral blood withdrawal to assay BAL fluids and serum samples for immune parameters. The BAL recoveries, cellularity, cell differentials, and lymphocyte subsets (CD19, CD3, CD4, CD8) did not show significant differences. IgG/albumin and IgA/albumin values were not significantly different, but IgA/albumin was significantly increased in the treatment (T0=0.14, 0.01 to 0.27, median and range, T90=0.15, 0.08 to 0.45, p=0.028) vs the placebo group when data from current smokers were excluded. Functional tests on alveolar macrophages (AM) (leading front stimulated motility and superoxide anion-O2/--release) showed a significant increase of random migration (T0=10.6, 7.0 to 23.6, T90=13.4, 8.1 to 28.8 μm, p=0.02) and of stimulated motility after FMLP 10- 7 M (T0=13.2, 8.3 to 46.4, T90=18.3, 8.4 to 49.6 μm, p=0.04), a significant increase of O2 - release in basal conditions (T0=6.0, 1.7 to 30.5 nM/106 AM/10', T90=11.1, 5.5 to 24.5, p=0.05) and after stimulation with opsonized zymosan (T0=17.7, 4.7 to 35.2, T90=22.1, 13.8 to 53.3, p=0.009) in the treatment group only. Data were not significantly different in the placebo group between T0 and T90. No modifications in systemic immunity were ever observed. Our data demonstrate that oral administration of a BE can increase immune defenses in the respiratory tract of patients with chronic bronchitis, without apparently altering systemic immunity. This confirms the possibility of a preferential traffic of immune information across the MALT and supports a rationale for experimental trials with oral treatments using BEs in the prevention of chronic bronchitis exacerbations.

AB - Bacterial extracts can act as immune stimulants and in some instances have been used, rather empirically, to prevent recurrent infections in the nonimmunocompromised host. Some agents are administered via oral route with the goal to increase airways immune defenses. In animal models and in normal humans, gut-associated lymphoid tissue (GALT) stimulation is able to induce a generalized response by the whole mucosal-associated lymphoid tissue (MALT). The aim of this placebo-controlled, double-blind, parallel-group study was to evaluate whether the stimulation of the GALT through oral administration of a polyvalent bacterial extract (BE) could lead to significant immune modifications either systemically or locally in the respiratory tract in patients suffering from chronic bronchitis. We selected 20 subjects (5 nonsmokers, 6 smokers, and 9 ex-smokers) for at least 3 years. According to a balanced-block randomization method, ten patients received active treatment and ten received placebo. Either drug or placebo was to be taken as one capsule daily the first 10 days of 3 consecutive months. Each capsule of the active product contained 7 mg of a BE obtained from eight different bacterial strains. On entry (T0) and 90 days after beginning of treatment (T90), all patients underwent bronchoalveolar lavage (BAL) and peripheral blood withdrawal to assay BAL fluids and serum samples for immune parameters. The BAL recoveries, cellularity, cell differentials, and lymphocyte subsets (CD19, CD3, CD4, CD8) did not show significant differences. IgG/albumin and IgA/albumin values were not significantly different, but IgA/albumin was significantly increased in the treatment (T0=0.14, 0.01 to 0.27, median and range, T90=0.15, 0.08 to 0.45, p=0.028) vs the placebo group when data from current smokers were excluded. Functional tests on alveolar macrophages (AM) (leading front stimulated motility and superoxide anion-O2/--release) showed a significant increase of random migration (T0=10.6, 7.0 to 23.6, T90=13.4, 8.1 to 28.8 μm, p=0.02) and of stimulated motility after FMLP 10- 7 M (T0=13.2, 8.3 to 46.4, T90=18.3, 8.4 to 49.6 μm, p=0.04), a significant increase of O2 - release in basal conditions (T0=6.0, 1.7 to 30.5 nM/106 AM/10', T90=11.1, 5.5 to 24.5, p=0.05) and after stimulation with opsonized zymosan (T0=17.7, 4.7 to 35.2, T90=22.1, 13.8 to 53.3, p=0.009) in the treatment group only. Data were not significantly different in the placebo group between T0 and T90. No modifications in systemic immunity were ever observed. Our data demonstrate that oral administration of a BE can increase immune defenses in the respiratory tract of patients with chronic bronchitis, without apparently altering systemic immunity. This confirms the possibility of a preferential traffic of immune information across the MALT and supports a rationale for experimental trials with oral treatments using BEs in the prevention of chronic bronchitis exacerbations.

UR - http://www.scopus.com/inward/record.url?scp=0027153340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027153340&partnerID=8YFLogxK

M3 - Article

C2 - 8404101

AN - SCOPUS:0027153340

VL - 103

SP - 1783

EP - 1791

JO - Chest

JF - Chest

SN - 0012-3692

IS - 6

ER -